Skip to main content
Clinical Trials/JPRN-jRCTs031180223
JPRN-jRCTs031180223
Recruiting
Phase 2

A phase 2 study of radio-chemotherapy for primary intracranial germ cell tumors - iGCT trial

Matsutani Masao0 sites210 target enrollmentMarch 8, 2019

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
primary intracranial germ cell tumors
Sponsor
Matsutani Masao
Enrollment
210
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 8, 2019
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Matsutani Masao

Eligibility Criteria

Inclusion Criteria

  • 1\.Primary intracranial germ cell tumors excluding mature teratoma.
  • 2\.Histologically\-confirmed intracranial germ cell tumors. If HCG\>\=2,000IU/ml and/or AFP\>\=2,000ng/ml, histology can be omitted.
  • 3\.The patient must not have any preceeding radiotherapy or chemotherapy.
  • 4\.Age\>\=4\.
  • 5\.ECOG\-PS of \<3\. PS\=3 is allowed if the impairment is solely from neurological disturbance brought by tumors.
  • 6\.Hematologic, renal, hepatic, and cardiac status should be documented within one week before registration.
  • \- White blood cell count \>3,000 per mm3
  • \- Absolute neutrophil count \> 1,500 per mm3
  • \- Platelets \>80,000 per mm3
  • \- Hemoglobin \>10\.0 grams

Exclusion Criteria

  • 1\. Previous malignancies.
  • 2\. Major renal, bladder, infectious illnesses, interstitial pneumonitis or pulmonary fibrosis, ischemic heart diseases, liver cirrhosis, bleeding, uncontrolled DM, or psychiatric impairments which in the investigator's opinion will prevent administration or completion of the protocol therapy.
  • 3\. Patients with known allergy to drugs used in the proposed regimens.
  • 4\. Patients taking warfarin.
  • 5\. patients pregnant or breast\-feeding a baby.
  • 6\. Patients, in the investigator's opinion, cannot complete the protocol study.

Outcomes

Primary Outcomes

Not specified

Similar Trials